Amneal Pharmaceuticals (AMRX) announced new positive interim results from its ongoing Phase 4 ELEVATE-PD study, presented at the Parkinson’s Study Group, PSG, Annual Meeting. The first 55 patients evaluated after six weeks of treatment demonstrated substantial clinical benefit after switching to CREXONT extended-release capsules, including significant increases in daily “Good On” time, reductions in “Off” time, improved motor symptom control, and consistent gains in “Good On” time per dose-regardless of whether patients switched from immediate-release carbidopa/levodopa, IR CD/LD with a COMT inhibitor, or RYTARY extended-release capsules.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal receives U.S. FDA approval for albuterol sulfate inhalation aerosol
- Closing Bell Movers: MongoDB jumps 22% on earnings beat and raise
- Amneal announces FDA approval of cyclosporine ophthalmic emulsion 0.05%
- Amneal Pharmaceuticals announces FDA approval for iohexol injection
- Amneal Pharmaceuticals Reports Strong Q3 Growth Amid Challenges